Sandoz CEO Warns: Donald Trump's Threat of 100%-200% Tariffs on Imported Generic Drugs Will Ultimately Be Borne by US Patients
Richard Saynor, CEO of Swiss pharmaceutical company Sandoz, stated in an interview with CNBC that no company would systematically continue to supply products at significant losses, thus manufacturers will face the choice of raising prices or ceasing supply. Donald Trump said in July that imported generic drugs could face a 100% tariff starting in 2028, potentially rising to 200% a year later, to encourage pharmaceutical companies to shift production to the United States.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
1SWAP Token: Project Status, Historical Review, and Market Analysis
-
2
WTI crude surged over 3.8% during trading, nearing $103.30 per barrel, while Brent crude rose nearly 3.8% to surpass $117.40 per barrel, driven by ongoing Middle East risks and short covering.
-
3
China's Cryptocurrency Regulatory Landscape and the Global Exchange Ecosystem
-
4
KENSHI (KNS) Analysis: Web3 Data Platform and Its Trading Status
-
5
MOOLAH Coin: A BEP20 Token on BNB Chain and Its Trading Guide
-
6
DCN (Dentacoin) Value Analysis: Is It Worth Long-Term Investment?
-
7
IMMO Coin Analysis: What is ImmortalDAO Finance (IMMO) and Where to Trade It
-
8
ELA Coin (Elastos) Status and Historical Review: 2023-2025 Forecasts and Actual Performance
-
9
BNT Coin: Total Supply and Current Status Analysis
-
10
Ukrainian officials state that SpaceX continues to restrict Starlink services, disconnecting drones exceeding 100 mph, despite Donald Trump's prior commitment to restore service.
Markets Today
Recommended Reading










